Healthcare provider profile · identity verified

Christopher Walcott, MD

Allopathic & Osteopathic Physicians|Family Medicine · RISING SUN, IN · NPI 1386931137

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Christopher Walcott, MD received $46.62 in general payments during 2025 across 3 reported records.

Astellas Pharma US Inc accounted for 35.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.

Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$46.62

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Astellas Pharma US Inc	Unresolved — no canonical attribution shown	$16.33	35.0%	1	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$15.86	34.0%	1	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$14.43	30.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$46.62	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Veozah Normalized: veozah	Drug	Astellas Pharma US Inc	$16.33	1	2025
Source payment records 2025-08-25 · Astellas Pharma US Inc · $16.33 · Open Payments source
LINZESS Normalized: linzess	Drug	ABBVIE INC.	$15.86	1	2025
Source payment records 2025-07-25 · ABBVIE INC. · $15.86 · Open Payments source
OTEZLA Normalized: otezla	Drug	Amgen Inc.	$14.43	1	2025
Source payment records 2025-04-11 · Amgen Inc. · $14.43 · Open Payments source
REPATHA Normalized: repatha	Biological	Amgen Inc.	$14.43	1	2025
Source payment records 2025-04-11 · Amgen Inc. · $14.43 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
LINZESS linzess	2025	Linzess	2024	67	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	67	15
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
Astellas Pharma US Inc Exact reporting entity; no affiliate inference	2025	Myrbetriq open payments reported associated product	CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014	Myrbetriq · 2024 Exact normalized brand match · 1 Part D row	35	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	757	116
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	664	96
Gabapentin	Gabapentin	605	80
Oxycodone Hcl	Oxycodone Hcl	528	51
Lisinopril	Lisinopril	507	105
Omeprazole	Omeprazole	475	91
Alprazolam	Alprazolam	405	51
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	403	54
Furosemide	Furosemide	400	84
Levothyroxine Sodium	Levothyroxine Sodium	351	57
Metformin Hcl	Metformin Hcl	346	59
Eliquis	Apixaban	333	39
Pantoprazole Sodium	Pantoprazole Sodium	314	66
Amlodipine Besylate	Amlodipine Besylate	308	69
Albuterol Sulfate Hfa	Albuterol Sulfate	292	77
Potassium Chloride	Potassium Chloride	286	36
Metoprolol Succinate	Metoprolol Succinate	285	58
Tamsulosin Hcl	Tamsulosin Hcl	265	45
Sertraline Hcl	Sertraline Hcl	263	41
Prednisone	Prednisone	233	70
Simvastatin	Simvastatin	223	57
Donepezil Hcl	Donepezil Hcl	222	23
Famotidine	Famotidine	219	43
Lorazepam	Lorazepam	185	31
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	175	31
Metoprolol Tartrate	Metoprolol Tartrate	175	31
Hydrochlorothiazide	Hydrochlorothiazide	173	44
Duloxetine Hcl	Duloxetine Hcl	167	26
Fluticasone Propionate	Fluticasone Propionate	163	39
Clopidogrel	Clopidogrel Bisulfate	159	26
Ropinirole Hcl	Ropinirole Hcl	156	25
Trazodone Hcl	Trazodone Hcl	152	27
Losartan Potassium	Losartan Potassium	145	28
Clonazepam	Clonazepam	138	17
Allopurinol	Allopurinol	133	24
Diazepam	Diazepam	133	26
Montelukast Sodium	Montelukast Sodium	132	31
Fluoxetine Hcl	Fluoxetine Hcl	131	14
Baclofen	Baclofen	124	20
Zolpidem Tartrate	Zolpidem Tartrate	124	18
Pregabalin	Pregabalin	120	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	117	23
Temazepam	Temazepam	117	18
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	115	12
Tramadol Hcl	Tramadol Hcl	112	17
Carvedilol	Carvedilol	111	21
Levetiracetam	Levetiracetam	111	11
Diclofenac Sodium	Diclofenac Sodium	108	29
Meloxicam	Meloxicam	105	26
Xarelto	Rivaroxaban	104	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	102	16
Ozempic	Semaglutide	101	17
Glimepiride	Glimepiride	99	26
Finasteride	Finasteride	96	15
Fluconazole	Fluconazole	96	28
Pravastatin Sodium	Pravastatin Sodium	92	26
Tizanidine Hcl	Tizanidine Hcl	88	23
Amitriptyline Hcl	Amitriptyline Hcl	87	24
Warfarin Sodium	Warfarin Sodium	85	14
Spironolactone	Spironolactone	83	16
Ibuprofen	Ibuprofen	80	25
Midodrine Hcl	Midodrine Hcl	78	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	76	14
Rosuvastatin Calcium	Rosuvastatin Calcium	76	23
Xifaxan	Rifaximin	76	suppressed
Mirtazapine	Mirtazapine	74	16
Alendronate Sodium	Alendronate Sodium	73	21
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	72	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	72	20
Ondansetron Odt	Ondansetron	72	20
Celecoxib	Celecoxib	70	16
Memantine Hcl	Memantine Hcl	69	suppressed
Hydralazine Hcl	Hydralazine Hcl	67	suppressed
Linzess	Linaclotide	67	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	60	45
Lactulose	Lactulose	60	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	59	35
Shingrix	Varicella-Zoster Ge/As01b/Pf	58	51
Buspirone Hcl	Buspirone Hcl	57	suppressed
Methocarbamol	Methocarbamol	57	15
Naproxen	Naproxen	57	16
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	56	15
Citalopram Hbr	Citalopram Hydrobromide	56	14
Doxycycline Hyclate	Doxycycline Hyclate	56	36
Carbidopa-Levodopa	Carbidopa/Levodopa	55	suppressed
Sucralfate	Sucralfate	54	14
Dicyclomine Hcl	Dicyclomine Hcl	53	13
Ipratropium Bromide	Ipratropium Bromide	53	20
Arexvy	Rsvpref3 Antigen/As01e/Pf	52	52
Escitalopram Oxalate	Escitalopram Oxalate	52	suppressed
Fentanyl	Fentanyl	52	suppressed
Nystatin	Nystatin	52	21
Topiramate	Topiramate	52	12
Novolog Flexpen	Insulin Aspart	51	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	50	43
Isosorbide Mononitrate Er	Isosorbide Mononitrate	50	suppressed
Farxiga	Dapagliflozin Propanediol	49	13
Ondansetron Hcl	Ondansetron Hcl	49	19
Estradiol	Estradiol	48	11
Olanzapine	Olanzapine	48	suppressed
Testosterone Cypionate	Testosterone Cypionate	48	suppressed
Digoxin	Digoxin	46	suppressed
Prazosin Hcl	Prazosin Hcl	46	suppressed
Propranolol Hcl	Propranolol Hcl	45	suppressed
Atenolol	Atenolol	44	suppressed
Meclizine Hcl	Meclizine Hcl	44	12
Metoclopramide Hcl	Metoclopramide Hcl	44	suppressed
Aripiprazole	Aripiprazole	43	suppressed
Lidocaine	Lidocaine	43	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	43	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	43	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	43	suppressed
Morphine Sulfate Er	Morphine Sulfate	42	suppressed
Azithromycin	Azithromycin	40	22
Loperamide	Loperamide Hcl	39	14
Spiriva Respimat	Tiotropium Bromide	39	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	39	24
Methadone Hcl	Methadone Hcl	38	suppressed
Amiodarone Hcl	Amiodarone Hcl	36	suppressed
Methylprednisolone	Methylprednisolone	36	15
Oxycontin	Oxycodone Hcl	36	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	35	12
Myrbetriq	Mirabegron	35	suppressed
Carisoprodol	Carisoprodol	34	suppressed
Nifedipine Er	Nifedipine	34	suppressed
Torsemide	Torsemide	34	suppressed
Incruse Ellipta	Umeclidinium Bromide	33	suppressed
Jardiance	Empagliflozin	33	suppressed
Metformin Hcl Er	Metformin Hcl	33	11
Lamotrigine	Lamotrigine	32	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	32	suppressed
Trulicity	Dulaglutide	32	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Cephalexin	Cephalexin	30	20
Doxepin Hcl	Doxepin Hcl	30	suppressed
Fenofibrate	Fenofibrate,micronized	30	suppressed
Ventolin Hfa	Albuterol Sulfate	30	suppressed
Eszopiclone	Eszopiclone	29	suppressed
Morphine Sulfate	Morphine Sulfate	29	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	28	suppressed
Divalproex Sodium	Divalproex Sodium	28	suppressed
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	26	suppressed
Labetalol Hcl	Labetalol Hcl	26	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	26	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Varenicline Tartrate	Varenicline Tartrate	26	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	25	suppressed
Nadolol	Nadolol	25	suppressed
Nystop	Nystatin	25	14
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	25	16
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Mupirocin	Mupirocin	24	suppressed
Promethazine Hcl	Promethazine Hcl	24	suppressed
Terazosin Hcl	Terazosin Hcl	24	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	23	suppressed
Humalog Kwikpen U-100	Insulin Lispro	23	suppressed
Ketoconazole	Ketoconazole	23	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	22	suppressed
Diltiazem 12hr Er	Diltiazem Hcl	22	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	22	suppressed
Klor-Con M20	Potassium Chloride	22	suppressed
Primidone	Primidone	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	21	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Glipizide Er	Glipizide	21	suppressed
Kapspargo Sprinkle	Metoprolol Succinate	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Nuplazid	Pimavanserin Tartrate	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	20	13
Tamoxifen Citrate	Tamoxifen Citrate	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Anastrozole	Anastrozole	19	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	19	suppressed
Tresiba Flextouch U-100	Insulin Degludec	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	17	suppressed
Cefdinir	Cefdinir	17	suppressed
Clotrimazole	Clotrimazole	17	suppressed
Dilt-Xr	Diltiazem Hcl	17	suppressed
Dropsafe Pen Needle	Pen Needle, Diabetic, Safety	17	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	17	suppressed
Glipizide	Glipizide	17	suppressed
Testosterone	Testosterone	17	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	17	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Memantine Hcl Er	Memantine Hcl	16	suppressed
Meropenem	Meropenem	16	suppressed
Tresiba Flextouch U-200	Insulin Degludec	16	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	15	suppressed
Clonidine	Clonidine	15	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	15	suppressed
Fiasp	Insulin Aspart (Niacinamide)	15	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	15	suppressed
Methimazole	Methimazole	15	suppressed
Vascepa	Icosapent Ethyl	15	suppressed
Xtampza Er	Oxycodone Myristate	15	suppressed
Insulin Aspart Flexpen	Insulin Aspart	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Silodosin	Silodosin	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Chlordiazepoxide Hcl	Chlordiazepoxide Hcl	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Metronidazole	Metronidazole	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Valsartan	Valsartan	13	suppressed
Betamethasone Valerate	Betamethasone Valerate	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Fluticasone-Salmeterol Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Levofloxacin	Levofloxacin	12	suppressed
Adderall Xr	Dextroamphetamine/Amphetamine	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Benztropine Mesylate	Benztropine Mesylate	11	suppressed
Dapagliflozin	Dapagliflozin Propanediol	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Mometasone Furoate	Mometasone Furoate	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Progesterone	Progesterone, Micronized	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$46.62 · 3 records	Astellas Pharma US Inc	LINZESS, OTEZLA, REPATHA, Veozah	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Linzess play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error